Adcendo inks $62m Series A

Adcendo, a developer of antibody-drug conjugates for the treatment of cancer, has raised $62 million in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this